Sign inJoin waitlistJoin the waitlist

Patricia Kropf

Associate Professor, Temple University/Fox Chase Cancer Center · University of California (San Francisco) School of Medicine

Credentials: · · · ·

History

University of California (San Francisco) School of Medicine
Present

University of Pittsburgh Health System
2008–2009
University of Pittsburgh Health System
2003–2006
Georgetown University School of Medicine
1999–2003

Research

Functional genomic landscape of acute myeloid leukaemia
Nature · 2018 · 1,111 citations
Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network · 2017 · 339 citations
Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial
The Lancet Oncology · 2017 · 125 citations

JI
Jean-Pierre Issa
10 papers
Hagop Kantarjian
6 papers
DS
David Snyder
5 papers
Gail Roboz
5 papers
Jason Gotlib
5 papers
Michael Deininger
5 papers
Camille Abboud
4 papers
Casey O'Connell
4 papers
Daniel Pollyea
4 papers
Elizabeth Griffiths
4 papers
Jessica Altman
4 papers
Joseph Moore
4 papers

Clinical trials

Leukemia SPORE Phase II DAC Study for R/R and Elderly Acute AML and MDS
Principal investigator · Completed · Phase 2
Fox Chase Cancer Center
2013–2020
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2024–2027
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2024–2029
A Study of APG-2575 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML)
Site PI · Unknown · Phase 1, Phase 2
Ascentage Pharma Group Inc.
2021–2024